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Abstract Human immunodeficiency virus (HIV) particles
that remain in the blood of patients are frequently ignored
as targets for AIDS treatment. We therefore investigated the
use of photodynamic therapy (PDT) with hematoporphyrin
monomethyl ether (HMME) as a means of inactivating cell-
free HIV in vitro. Virus particles including HIV-1IIIB,
resistant HIV-1 variants, HIV-1 clinical variants, and HIV-
2 variants were incubated with HMME for 40 min,
followed by irradiation with a 630-nm semiconductor laser
at an energy density of 0.3 J/cm2. The antiviral effects were
evaluated by counting syncytium formation or measuring
p24 antigen expression levels in supernatants by enzyme-
linked immunosorbent assay. The relationships between
photoinactivation and HMME concentrations, energy den-
sity, power density and antioxidants (NaN3 and D-mannitol)
were also assessed using the above methods. All the tested
virus particles were completely responsive to HMME-PDT.
HMME concentration and energy density were positively
correlated with photoinactivation of HIV, while power
density was negatively correlated. Both sodium azide and
D-mannitol weakened the inhibitory effect of PDT on virus-
induced membrane fusion, with D-mannitol having a
stronger effect. HMME-PDT can inactivate HIV particles,
and may therefore represent a promising treatment for
AIDS patients.
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Introduction
HIV (human immunodeficiency virus) was identified as the
causative agent of AIDS (acquired immunodeficiency
syndrome) about 28 years ago [1, 2]. HIV replicates in
CD4+ T cells and macrophages, producing infectious
particles from multiple intracellular events. Chemicals that
act against these intracellular events, especially reverse
transcription, integration, and processing, have been suc-
cessfully generated, and HIV replication and disease
progression can now be effectively suppressed by admin-
istration of a combination of these chemicals [3, 4].
However, the therapeutic relevance of cell-free HIV
particles has been neglected. HIV particles persist in the
blood vessels at varying loads from the time of infection
until death. Although some of the particles can be
eliminated by the patient’s immune system, others remain
to infect new host cells and promote disease progression.
AIDS progression could thus be effectively suppressed if
these cell-free particles could be promptly eradicated as
they are produced.
Photodynamic therapy (PDT) is a two-step therapeutic
technique in which the topical or systemic delivery of
photosensitizing drugs is followed by irradiation with visible
light. Activated photosensitizers transfer energy to molecular
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oxygen, generating reactive oxygen species. The subsequent
oxidation of lipids, amino acids and proteins induces cell
necrosis and apoptosis [5]. The study of photoinactivation of
HIV in blood products was a focus of intense investigation in
the 1990s, and PDT was shown to be effective against HIV
particles [6, 7], though the side effects, especially the
potential teratogenicity of photosensitizers, and technical
issues associated with the use of lasers have hampered
research in vivo. However, many new photosensitizers with
weak side effects are now emerging. Hematoporphyrin
monomethyl ether (HMME) is a novel, second-generation
porphyrin-related photosensitizer that displays many of the
ideal characteristics of effective photoantimicrobials. Exper-
imental studies and clinical trials have shown that it has a
simple, monomolecular structure, is selectively taken up by
tumor tissues, has a stronger photodynamic effect that yields
eight times more singlet oxygens and demonstrates lower
toxicity and shorter-term skin photosensitization than hema-
toporphyrin derivatives [8, 9]. HMME is thus a promising
photosensitizer for PDT, but no reports on the antiviral
activity of HMME-PDT have yet been published. In this
study, we therefore investigated the efficacy of HMME-PDT




HMME (12 mg/ml, 10 ml) was purchased from Shanghai
Fudan-zhangjiang Bio-Pharmaceutical Company (China).
Methylene blue (MB) injection (1 mg/ml) was purchased from
the Emergency Pharmacy of Tianjin Medical University
General Hospital (China). A semiconductor laser with an output
at a wavelength of 630 nm was manufactured by the Laser
Medicine Laboratory, Institute of Biomedical Engineering,
Chinese Academy of Medical Sciences. NaN3 and D-mannitol
were purchased from Sigma. Horseradish peroxidase-labeled
goat anti-human IgG was purchased from Sino-America
Biotechnology Company (China). The p5F1 monoclonal
antibody against HIV-1 p24 was prepared in the laboratory
of Professor Zheng [10] (Kunming Institute of Zoology,
Chinese Academy of Sciences, Kunming, China). Human
polyclonal anti-HIV-1 serum was kindly donated by Dr. Hiroo
Hoshino (Gunma University School of Medicine, Japan).
Cells and viruses
The laboratory-derived viruses HIV-1IIIB, HIV-2CBL-20, HIV-
2ROD, HIV-1IIIB A17, protease-inhibitor resistant HIV-1
variants (HIV-1 L10R/M46I/L63P/V82T/I84V; HIV-1 prote-
ase gene mutants RF/V82F/184V) and enfuvirtide-resistant
HIV-1 variants (pNL4-3 gp41 (36G) N42S; pNL4-3 gp41
(36G) V38A, N42T) were obtained from the NIH AIDS
Research and Reference Reagent Program and the MRC
AIDS Reagent Project. Clinically isolated HIV-1KM018 was
obtained from a naive HIV-1-infected individual from Yunnan
Province, China, as previously described [11]. All the virus
variants were cultured in Professor Zheng’s laboratory. Cell
lines (C8166, MT-4, H9/HIV-1IIIB) were maintained in RPMI-
1640 supplemented with 10% heat-inactivated fetal calf serum
(Gibco). The cells used in all experiments were in log-phase
growth. Peripheral blood mononuclear cells (PBMCs) from
healthy donors were isolated by Ficoll-Hypaque centrifuga-
tion, and incubated in complete medium containing 5 μg/ml
phytohemagglutinin (Sigma) for 72 h prior to use in antiviral
assays. The 50% tissue culture infectious dose (TCID50) of
HIV strains in C8166 cells was determined and calculated
using the method of Reed and Muench [12]. Virus stocks
were stored in aliquots at −70°C. The titer of the virus stock
was 3.4×106 TCID50 per ml.
PDT
HMME was used as the photosensitizer in the experiments,
withMB as a positive control. MB is an established biological
stain and effective photosensitizer with limited in vivo use
because of its potential mutagenic effects. A 630-nm
wavelength semiconductor laser was developed in our
laboratory. The core diameter of the output optical fiber was
400 μm and the numerical aperture was 0.22. The PDT
protocol was as follows. Virus suspensions were incubated
with HMME or MB at concentrations in the range 0–100 μg/
ml for a specific time, followed by irradiation using the
semiconductor laser. The power density and irradiation
duration were set at different values in different experiments.
After PDT, viruses were incubated with host cells and
photoinactivation was assessed by detecting the infection rate.
Incubation periods
A total of 50 μl HIV-1IIIB stock solution was mixed with
50 μl HMME (10 μg/ml) and incubated in 5% CO2 at 37°C
for various times (0–80 min). The mixture was then
irradiated with 20 mW/cm2 for 1 min, diluted 100 times
and mixed with 104 C8166 (multiplicity of infection, MOI,
0.3) and incubated for up to 3 days in a CO2-enriched
atmosphere in an incubator at 37°C. The number of
syncytia was counted and the percentage deactivation was
calculated relative to the control group.
Photoinactivation
The HIV-1IIIB, HIV-2 strains (HIV-2CRL20 and HIV-2ROD),
resistant HIV-1 strains (HIV-1IIIBA17, HIV-1 L10R/M46I/
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L63P/V82T/I84V, HIV-1 protease gene mutants RF/V82F/
184V, pNL4-3 gp41 (36G) N42S, pNL4-3 gp41 (36G)
V38A, N42T) and HIV-1 clinical strains (HIV-1KM018)
were subjected to PDT as described above. After PDT, HIV-
1IIIB, HIV-2 strains and resistant HIV-1 strains were used to
infect C8166 cells (105/ml, MOI 0.3) for 3 days. The
number of syncytia was counted for HIV-2 strains, and the
level of p24 antigen in the culture supernatant was tested by
enzyme-linked immunosorbent assay (ELISA), as described
by Zheng et al. [10] for HIV-1-resistant strains. Briefly,
Triton X-100-treated cell-free culture supernatant was
added to 96-well microtiter plates coated with monoclonal
antibody p5F1. Plates were then incubated with diluted
human polyclonal anti-HIV-1 serum, followed by incuba-
tion with horseradish peroxidase-labeled goat anti-human
IgG, and o-phenylenediamine substrate was added. The
optical density of each well was read using a Bio-Tek ELx
800 ELISA reader at 490/630 nm. The percentage
inhibition of p24 antigen expression was calculated for
each well and a dose-response curve was constructed.
HIV-1KM018 strain was added to PBMCs (20% of total,
MOI 0.04). After incubation for 2 h, the remaining PBMCs
(80% of total) were added and the cultures were incubated
in RPMI-1640 with interleukin-2 (50 U/ml) at 37°C for
7 days, with fresh medium supplied every 3 days. The level
of p24 antigen in the culture supernatant was tested by
ELISA as described above.
Factors affecting photoinactivation
Energy density, power density, photosensitizer, and oxygen
can potentially influence the outcome of PDT. We
determined the effects of these factors on the inactivation
of HIV-1IIIB by PDT by varying their values. Concen-
trations of HMME were set at fivefold dilution in the range
0–100 μg/ml. In the experiments for energy density, the
power density was set at 20 mW/cm2, and the irradiation
time was varied from 15 s to 4 min. For power density, the
energy density was fixed at 1.2 J/cm2, and the power
density was set at 5, 20 or 80 mW/cm2. After PDT, all
treated viruses were used to infect MT-4 cells, and the
protection rates of infected MT-4 cells were used as a
measure of the inhibitory effects on the virus.
In the case of oxygen, one of two antioxidants, sodium
azide (10 μM) or D-mannitol (40 μM), or both, was added
to the reaction medium throughout the whole procedure.
We performed two different antioxidant experiments, one
using cell-free HIV-1 particles and the other using cell-
associated HIV-1 in the process of virus–cell membrane
fusion. The protocol for the latter experiment was as
follows. Photosensitizer was added to HIV-1IIIB virus
stocks at a 1:1 ratio and incubated at 37°C for 40 min.
The mixture was then diluted 100-fold and added to 104
C8166 cells (MOI 0.3) and incubated for 1 h at 4°C to
allow virus binding. The virus–cell mixture was washed
three times with phosphate-buffered saline to remove extra
photosensitizer and free virus. The virus–cell mixture was
resuspended in RPMI-1640 and seeded in 96-well micro-
titer plates. After incubation for different times at 37°C, the
cells were irradiated at an energy density of 0.3 J/cm2. p24
antigen expression in the culture supernatant was measured
after 3 days, as described previously. The percentage
inactivation of virus was calculated relative to the control
group.
Statistical analysis
Data were processed using the SPSS software package
(version 13.0). Data are shown as means ± SD or SE, unless
otherwise stated, and p values of <0.05 were considered
significant. Experiments were performed at least three times
and data from representative experiments are presented.
Results
Optimal incubation time for photosensitizers
We determined the efficacy of photoinactivation with
photosensitizers for different incubation times and deter-
mined the optimal incubation duration to be used in
subsequent experiments. The results are shown in Fig. 1.
The change in the curve from a sharp to a gentle gradient
occurred at 40 min for HMME and 10 min for MB. We
therefore selected 40 min as the optimal incubation period
in subsequent experiments.

































Fig. 1 Duration of incubation with photosensitizers for HIV-1IIIB. The
efficacy of PDT was determined by counting syncytium formation.
The concentration of photosensitizer was set at 10 μg/ml. Error bars
represent the standard deviation
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Virus inactivation
To determine if PDT had broad-spectrum activity against
HIV, we evaluated the responses of HIV-1, HIV-2, resistant
HIV, and HIV clinical strains to PDT. The inactivating
effects of PDT were assessed in terms of the inhibition of
syncytium formation or p24 antigen production after
infection, compared to nontreated virus. As shown in
Fig. 2, all the tested variants were significantly deactivated
by PDT treatment. When the dose of HMME was increased
to 20 μg/ml or that of MB to 5 μg/ml, the response curves
for almost all variants changed from a sharp to a gentle
gradient. When the photosensitizer concentrations were
increased to 100 μg/ml, the virus inactivation rates were
almost 100%.
PDT variables
Energy density, power density and photosensitizer concen-
tration are the three basic variables of PDT, and we
therefore examined their contributions to the anti-HIV
activities of PDT.
Photosensitizer dose Photoinactivation was represented by
the protection of infected MT4 cells (Fig. 3). The survival
rate of MT4 cells increased with increasing photosensitizer
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Fig. 2 a–c Inactivation of HIV-1IIIB, HIV-2, resistant HIV-1 and HIV-
1 clinical strains induced by PDT HIV-1IIIB (a), HIV-2CRL20 (b) and
HIV-2ROD (c). The efficacy of PDT was expressed as the inhibition
rate of syncytium formation. d, e Inactivation of protease inhibitor-
resistant HIV-1 variants HIV-1 L10R/M46I/L63P/V82T/I84V (d) and
HIV-1 protease gene mutants RF/V82F/184V (e). f, g Efficacy of PDT
against the enfuvirtide-resistant HIV-1 variants pNL4-3 gp41 (36G)
N42S (f) and pNL4-3 gp41 (36G) V38A, N42T (g). h, i Inactivation
of the reverse transcriptase non-nucleoside inhibitor-resistant variant
HIV-1IIIB A17 (h) and HIV-1KM018 (i). p24 antigen production was
used as a measure of PDT-induced inactivation of HIV-1-resistant and
clinical variants
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dose in the range 0–100 μg/ml when the energy density and
power density remained the same, suggesting that the
efficacy of PDT depended on the concentration of
photosensitizer.
Energy density The efficacy of PDT against HIV was also
dependent on energy density, increasing in the order 0.3 J/
cm2<1.2 J/cm2<4.8 J/cm2 at a power density of 20 mW/
cm2, as shown in Fig. 3.
Power density The anti-HIV activity of PDT was also
inversely proportional to the power density at 1.2 J/cm2, in
the order 5 mW/cm2>20 mW/cm2>80 mW/cm2 (Fig. 4).
However, at HMME doses below 40 μg/ml, the photo-
inactivation effect was greatest at 80 mW/cm2. The reason
for this may be that the energy of light and oxygen is
enough for HMME excitation at HMME doses below
40 μg/ml, so the increased virus death at 80 mW/cm2
would be caused by thermal injury from the laser.
Antioxidants
We investigated the abilities of the singlet-oxygen quencher
sodium azide and the hydroxyl radical scavenger D-
mannitol to protect the virus from PDT-induced inactiva-
tion. Virus activity was expressed as p24 antigen produc-
tion in treated virus as a percentage of that in the control
virus. There were no significant differences in p24 antigen
production between any of the groups in the cell-free
experiments (Fig. 5). This may have been because of a lack
of necessary enzymes and substrates in the medium.
In the cell-associated virus experiments, however, p24
antigen production was lower in the PDT group than in the
groups with added sodium azide, D-mannitol, or sodium
azide plus D-mannitol, at all time points after adhesion. In
the absence of antioxidants, HMME-PDT reduced p24
antigen production in the medium after adhesion to
20.38%, 27.49%, 40.37% and 98.20% of control at 0, 15,
30 and 60 min (p<0.05), respectively. However, the
inhibitory effect of PDT on p24 antigen production was
significantly blocked by 10 μM sodium azide, 40 μM D-
mannitol, and the combination of the two. D-Mannitol had a
greater effect than sodium azide, while the combination of
the two had the greatest effect (Fig. 6a). Both antioxidants
also weakened the inhibitory effect of MB-PDT on p24
antigen production, with D-mannitol alone having the
greatest effect (Fig. 6b).
Discussion
In previous studies we assessed the ability of PDT to inhibit
the infection of host cells by HIV, including its effects on
viral entry, reverse transcription, integration, duplication,
translation, and assembly of the HIV replication cycle, as
well as its ability to inactivate cell-free HIV [13]. HMME-
PDT inhibited membrane fusion (the process of HIV entry)
induced by HIV-1IIIB and deactivated cell-free HIV-1IIIB,
suggesting that PDT may represent a promising new
treatment for HIV-infected individuals. Cell-free HIV
particles represent an important target for PDT, and we
therefore investigated the responses of different HIV
isoforms, including HIV-1 and HIV-2 variants, resistant
HIV-1 variants and HIV-1 clinical variants to HMME-PDT.
Since the initial description of HIV-1 in 1983 [1] and
HIV-2 in 1986 [14], these two viruses have been identified
as the primary causes of AIDS. HIV-1 is the major cause of




































































































Fig. 3 Anti-HIV activities of PDT at different photosensitizer
concentrations and different energy densities. The photosensitizer
dose ranged from 0 to 100 μg/ml, and the power density was fixed at
20 mW/cm2 (a HMME, b MB)
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AIDS in the world today, but although most anti-AIDS
therapies therefore focus on HIV-1 infection, HIV-2 remains a
potential problem. The results of the current study showed
that not only was PDT with HMME able to inactivate up to
100% of HIV-1IIIB particles, but also up to 100% of HIV-
2CRL20 and HIV-2ROD particles, suggesting that it might
provide a useful treatment for AIDS patients in most parts of
the world. The development of resistant viral strains is one of
the main reasons for virological failure of anti-HIV therapy
[15]. The current results showed that a series of resistant HIV
strains, including those resistant to protease inhibitors
(HIV-1 L10R/M46I/L63P/V82T/I84V and HIV-1 protease
gene mutants RF/V82F/184V), enfuvirtide (pNL4-3 gp41
(36G) N42S and pNL4-3 gp41 (36G) V38A, N42T) and
reverse transcriptase non-nucleoside inhibitors (HIV-1IIIB
A17), were all completely responsive to PDT, indicating
that this might also represent a useful therapeutic strategy
in patients with drug-resistant AIDS. We also determined
the effects of PDT on the clinical strain HIV-1KM018
(obtained from a naive HIV-1-infected individual from
Yunnan Province, China) and demonstrated complete
inactivation at HMME concentrations >20 μg/ml.
Overall these studies suggest that HMME-PDT could
provide a useful treatment for AIDS patients infected with
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Fig. 5 Effects of antioxidants on the ability of PDT to inactivate cell-free virus (a HMME-PDT, b MB-PDT) (+N addition of 10 μM NaN3, +D
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Fig. 4 Anti-HIV activities of PDT at different power densities. The photosensitizer dose ranged from 0 to 100 μg/ml, and the energy density was
fixed at 1.2 J/cm2 (a HMME, b MB)
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most kinds of HIV strains. HMME-PDT targets cell-free
HIV particles, which could be accessed in clinical practice
via extracorporeal circulation.
However, HMME-PDT is a multifactor therapy and its
effects can vary depending on the parameters used.
Photosensitizer, light, and oxygen form the basic compo-
nents of PDT. For example, the molecular structure,
molecular charge and relative hydrophobicity of the
photosensitizer are important determinants of antiviral
activity [6]. Positively charged photosensitizers are report-
edly cause nucleic acid damage more effectively than their
neutral anionic congeners. However, the latter are more
sensitive to the membrane, and enveloped viruses thus
respond more sensitively to anionic photosensitizers, while
non-enveloped viruses are more sensitive to cationic ones.
HMME is an anionic photosensitizer and HIV is an
enveloped virus. According to the theory above, HMME
should thus be more effective against HIV than the cationic
MB. Moreover, the potential mutagenic effects of MB
restrict its use in clinical practice [16]. Our previous study
also confirmed that the cytotoxicity of MB is higher than
that of HMME. Both these factors make HMME a more
suitable photosensitizer for the treatment of AIDS.
The results of this study confirmed that photosensitizer dose
and light are important determinants of the antiviral activity of
PDT. The degree of photodamage to HIV strains depended on
the concentration of HMME and the energy of the light. Higher
concentrations and increased light energy were associated with
increased anti-HIV activities. Power density has also been
identified as an important modulator of tissue oxygenation and
treatment outcome in PDT. Henderson et al. [17] reported that
severe oxygen depletion occurs within seconds of illumina-
tion at a fluence rate of 75 mW/cm2 in radiation-induced
fibrosarcoma tumors photosensitized with AlPcS2, and they
found that power density affected the response of tumors to
PDT in the Colon 26 tumor model. High power densities
reduced or even totally inhibited tumor control, while low
power densities promoted tumor control. Our results are in
agreement with those of Henderson et al., in that PDT at a
low power density (5 mW/cm2) killed more HIV virus
particles than at a high density (80 mW/cm2), as long as a
high enough concentration of photosensitizer was used. If the
concentration of photosensitizer was insufficient, its levels
were exhausted before the oxygen was depleted.
The production of reactive oxygen species, specifically
singlet oxygen, is another factor determining the outcome
of PDT. The photosensitizer in its ground state is excited to
its singlet state by a laser emitting at a suitable wavelength.
After intersystem crossing to the triplet state, the photosen-
sitizer can react with oxygen via an energy transfer process
to generate singlet oxygen (1O2; type II reaction), or can
participate in electron transfer processes, leading to radical
formation (type I reaction). Both type I and type II reactions
can occur during PDT, but type II reactions usually play a
major role [18, 19]. Understanding the major reaction type
is important for improving the clinical efficacy of PDT.
Two antioxidants, the singlet oxygen quencher sodium
azide and the hydroxyl radical scavenger D-mannitol, were
used to identify the reaction type in the current study, and
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Fig. 6 The effects of antioxidants on the ability of PDT to inhibit cell-virus membrane fusion (a HMME-PDT, b MB-PDT) (+N addition of
10 μM NaN3, +D addition of 40 μM D-mannitol)
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simultaneously during anti-HIV HMME-PDT, with type I
reactions playing a major role.
In conclusion, photoinactivation of HIV by HMME
was dependent on the photosensitizer used, light and
oxygen. Thus the outcome of PDT could be improved by
adjusting the parameters used. The results also demon-
strated that most kinds of HIV strains are responsive to
HMME-PDT, which therefore represents a promising
treatment for AIDS patients. Further studies are planned
to identify the molecular mechanisms responsible for the
inactivation of HIV particles by HMME-PDT, and to
investigate the safety and effectiveness of HMME-PDT
for treating AIDS using extracorporeal circulation in
animal experiments.
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